Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine

Journal of Pharmacy and Pharmacology

Volumn 58, Issue 3, 2006, Pages 337-344

  Liu, Kuo Sheng ^a,b   Kao, Cheng Hsiung ^b   Liu, Shyun Yeu ^b   Sung, K C ^c   Kuei, Chun Hsiung ^a   Wang, Jhi Joung ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIS OIL; BUPRENORPHINE; CASTOR OIL; COTTON SEED OIL; LONG ACTING DRUG; MORPHINE; NALOXONE; SESAME SEED OIL; SOYBEAN OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN;

ANIMALS; BUPRENORPHINE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; MALE; MICE; MORPHINE DEPENDENCE; NARCOTIC ANTAGONISTS; SESAME OIL;

EID: 33644785800     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.58.3.0007     Document Type: Article

References (27)

1. Allen, L. V., Popovich, N. G., Ansel, H. C. (2005a) Drug dosage form and drug delivery system design: biopharmaceutic and pharmacokinetics considerations. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edn, Lippincott Williams & Wilkins, Philadelphia, pp 142-185
2. Allen, L. V., Popovich, N. G., Ansel, H. C. (2005b) Sterile dosage forms and delivery systems: Parenterals. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edn, Lippincott Williams & Wilkins, Philadelphia, pp 443-505
3. Assadi, S. M., Hafezi, M., Mokri, A., Razzaghi, E. M., Ghaeli, P. (2004) Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J. Subst. Abuse Treat. 27: 75-82
4. Barnett, P. G., Rodgers, J. H., Bloch, D. A. (2001) A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96: 683-690
5. Bickel, W. K., Amass, L. (1995) Buprenorphine treatment of opioid dependence: a review. Exp. Clin. Psychopharmacol. 3: 477-489
6. Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I.A., Jasinski, D. R., Johnson, R. E. (1988) A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43: 72-78
7. Brewer, C. (1997) Ultra-rapid, antagonist-precipitated opiate detoxification under general anesthesia or sedation. Addict. Biol. 2: 291-302
8. Bulka, A., Kouya, P. F., Bottiger, Y., Svensson, J. O., Xu, X. J., Wiesenfeld-Hallin, Z. (2004) Comparison of the antinociceptive effect of morphine, methadone, buprenorphine and codeine in two substrains of Sprague-Dawley rats. Eur. J. Pharmacol. 492: 27-34
9. Cheskin, L. J., Fudala, P. J., Johnson, R. E. (1994) A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 36: 115-121
10. Davids, E., Gastpar, M. (2004) Buprenorphine in the treatment of opioid dependence. Eur. Neuropsychopharmacol. 14: 209-216
11. Davis, M. P. (2005) Buprenorphine in cancer pain. Support. Care Cancer 13: 878-887
12. El-Kadi, A. O., Sharif, S. I. (1994) The influence of various experimental conditions on the expression of naloxone-induced withdrawal symptoms in mice. Gen. Pharmacol. 25: 1505-1510
13. Janiri, L., Mannelli, P., Persico, A. M., Serretti, A., Tempesta, E. (1994) Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 36: 139-145
14. Kest, B., Palmese, C. A., Hopkins, E., Adler, M., Juni, A. (2001) Assessment of acute and chronic morphine dependence in male and female mice. Pharmacol. Biochem. Behav. 70: 149-156
15. Kest, B., Palmese, C. A., Hopkins, E., Adler, M., Juni, A., Mogil, J. S. (2002) Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115: 463-469
16. Kosten, T. R. (2003) Buprenorphine for opioid detoxification: a brief review. Addict. Disord. Treat. 2: 107-112
17. Law, F. D., Myles, J. S., Daglish, M. R. C., Nutt, D. J. (2004) The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatr. 16: 246-274
18. Lewis, J. W. (1985) Buprenorphine. Drug Alcohol Depend. 14: 363-372
19. Liu, K. S., Hu, O. Y. P., Ho, S. T., Tzeng, J. I., Chen, Y. W., Wang J. J. (2004) Antinociceptive effect of a novel long-acting nalbuphine preparation. Br. J. Anaesth. 92: 712-715
20. Nigam, A. K., Ray, R., Tripathi, B. M. (1993) Buprenorphine in opiate withdrawal: a comparison with clonidine. J. Subst. Abuse Treat. 10: 391-394
21. 3 analgesia. Brain Res. 744: 41-46
22. Roy, S. D., Roos, E., Sharma, K. (1994) Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci. 83: 126-130
23. Sigmon, S. C., Wong, C. J., Chausmer, A. L., Liebson I. A., Bigelow, G. E. (2004) Evaluation of injection depot formulation of buprenorphine: placebo comparison. Addiction 99: 1439-1449
24. Sobel, B. F. X., Sigmon, S. C., Walsh, S. L., Johnson, R. E., Liebson, I. A., Nuwayser, E. S., Kerrigan, J. H., Bigelow, G. E. (2004) Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. 73: 11-22
25. Tornay, C. B., Favrat, B., Monnat, M., Daeppen, J. B., Schnyder, C., Bertschy, G. (2003) Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results. Drug Alcohol Depend. 69: 283-288
26. Umbricht, A., Montoya, I. D., Hoover, D. R., Demuth, K. L., Chiang, C. T., Preston, K. L. (1999) Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend. 56: 181-190
27. Walsh, S. L., Preston, K. L., Bigelow, G. E., Stitzer, M. L. (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effect. J. Pharmacol. Exp. Ther. 274: 361-372